CAR T-Cell Therapy Failure Linked to Senescent CD8+ T Cells
The poor initial quality of a patient’s harvested CD8+ T cells that are used to manufacture CAR T-cells lacks the ability to mount a robust immune response. The...
The poor initial quality of a patient’s harvested CD8+ T cells that are used to manufacture CAR T-cells lacks the ability to mount a robust immune response. The post CAR T-Cell Therapy Failure Linked to Senescent CD8+ T Cells appeared first on Inside Precision Medicine .